Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 43,000 full-time employees.  The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. The company is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).

Eli Lilly & Co. terlibat dalam penemuan, pengembangan, produksi, dan penjualan produk farmasi. Perusahaan berpusat di Indianapolis, Indiana dan saat ini memiliki 43.000 karyawan penuh waktu. Perusahaan menemukan, mengembangkan, memproduksi, dan memasarkan produk dalam segmen produk farmasi manusia. Produk diabetes, obesitas, dan kardiometabolik lainnya termasuk Basaglar, Humalog, Mounjaro, Trulicity, dan Zepbound. Produk onkologi termasuk Alimta, Retevmo, Tyvyt, dan Verzenio. Produk imunologi termasuk Ebglyss, Olumiant, Omvoh, dan Taltz. Produk neurosains termasuk Cymbalta dan Emgality. Produk dan terapi lainnya termasuk Cialis dan Forteo. Perusahaan memproduksi dan mendistribusikan produknya melalui fasilitas di Amerika Serikat (AS), termasuk Puerto Rico, serta di Eropa dan Asia. Perusahaan, melalui anak perusahaannya, POINT Biopharma Global Inc., terlibat dalam penemuan, pengembangan, dan produksi radiofarmasi, serta terapi radioligand klinis dan praklinis. Perusahaan juga sedang mengembangkan inhibitor molekul kecil oral dari α4β7 integrin (dikenal sebagai MORF-057) untuk penyakit radang usus (IBD).

Eli Lilly

Tentang Eli Lilly

Statistik Kunci